Lifecore Biomedical (LFCR) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 93.4% versus a loss of 16.4%. Over five years, LFCR leads with a -26.3% price change compared with -76.9% for PRLD. Prelude Therapeutics is the larger company by market cap ($258.6 million vs $242.2 million), about 1.1 times the size.
Lifecore Biomedical converts more of its revenue into profit, with a net margin of -30.0% versus -819.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFCR | PRLD |
|---|---|---|
| Share price | $6.39 | $3.23 |
| Market cap | $242.22M | $258.63M |
| 1-day change | +0.31% | -0.77% |
| YTD return | -21.88% | +11.38% |
| 1-year return | -16.36% | +93.41% |
| 5-year return | -26.30% | -76.93% |
| EPS (TTM) | $-1.27 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $128.87M | $12.14M |
| Revenue growth (YoY) | +0.47% | +73.43% |
| Net income (latest FY) | $-38.72M | $-99.50M |
| Gross margin | 31.27% | — |
| Operating margin | -13.38% | -861.33% |
| Net margin | -30.04% | -819.59% |
| 52-week high | $8.98 | $6.83 |
| 52-week low | $3.63 | $1.30 |
| Distance from 52-week high | -28.84% | -52.71% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -1.72% | +172.45% |
| Average volume | 414.71K | 432.74K |
| Shares outstanding | 37.91M | 65.34M |
| Employees | 382 | 79 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed LFCR by 109.8 percentage points over the past year.
- Lifecore Biomedical is more profitable, keeping -30.0 cents of every revenue dollar as net income versus -819.6 cents for Prelude Therapeutics.
- Prelude Therapeutics grew revenue faster in its latest fiscal year (+73.43% vs +0.47%).
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
LFCR vs PRLD FAQ
Which is bigger, Lifecore Biomedical or Prelude Therapeutics?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $258.63M compared with $242.22M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, LFCR or PRLD?
PRLD returned +93.41% over the past 12 months, compared with -16.36% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are Lifecore Biomedical and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.